Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Teamwork Financial Advisors LLC

Teamwork Financial Advisors LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 616.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 31,883 shares of the company’s stock after purchasing an additional 27,431 shares during the period. Teamwork Financial Advisors LLC’s holdings in Novo Nordisk A/S were worth $2,214,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. M. Kulyk & Associates LLC raised its position in shares of Novo Nordisk A/S by 3.9% in the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company’s stock valued at $274,000 after purchasing an additional 119 shares in the last quarter. Center for Financial Planning Inc. increased its stake in shares of Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the last quarter. Tradewinds Capital Management LLC raised its holdings in Novo Nordisk A/S by 2.6% in the fourth quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company’s stock valued at $429,000 after acquiring an additional 124 shares in the last quarter. Exencial Wealth Advisors LLC boosted its stake in Novo Nordisk A/S by 0.5% during the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company’s stock valued at $1,987,000 after acquiring an additional 124 shares during the last quarter. Finally, Indie Asset Partners LLC grew its holdings in Novo Nordisk A/S by 4.2% during the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company’s stock worth $269,000 after acquiring an additional 126 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on NVO. Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, April 28th. Wall Street Zen upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 25th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Guggenheim downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $128.00.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $70.90 on Wednesday. The company has a market cap of $318.17 billion, a PE ratio of 21.55, a P/E/G ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The firm has a 50-day simple moving average of $65.62 and a 200 day simple moving average of $81.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting analysts’ consensus estimates of $0.92. The company had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.